Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 11, 2023 12:00 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience Presents VGL101 Complete Phase 1 Data and Phase 2 IGNITE Trial Design at the 2023 American Neurological Association Annual Meeting

- Complete Phase 1 data analysis demonstrated that VGL101 continued to have a favorable safety and tolerability profile and proof-of-target engagement in SAD/MAD cohorts up to 60 mg/kg - - On track...
September 08, 2023 16:05 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience Announces Update on its Small Molecule TREM2 Agonist Program

- Announced VG-3927 as lead candidate to enter clinical development for potential treatment of Alzheimer’s Disease - - IND for VG-3927 now open; Phase 1 clinical trial in healthy volunteers allowed...
September 08, 2023 07:05 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience to Present at 2023 Morgan Stanley Global Healthcare Conference

WATERTOWN, Mass., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
August 08, 2023 07:05 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience Reports Second Quarter 2023 Financial Results and Provides Business Update

- Interim data from 20 mg/kg cohort in IGNITE Phase 2 clinical trial of VGL101 in people living with ALSP expected in fourth quarter of 2023 - - Small molecule TREM2 agonist IND submission and...
August 07, 2023 16:05 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience Appoints Christopher J. Silber, M.D. as Chief Medical Officer

WATERTOWN, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
June 01, 2023 07:00 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience to Present at 2023 Jefferies Global Healthcare Conference

WATERTOWN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...
May 10, 2023 07:00 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience Reports First Quarter 2023 Financial Results and Provides Business Update

- Partial clinical hold lifted by FDA on VGL101 - - Launched ALSPAware to provide access to no-cost genetic testing and counseling for ALSP - - Appointed distinguished biopharmaceutical industry...
May 09, 2023 07:00 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience Appoints Samantha Budd Haeberlein, Ph.D. to Board of Directors

WATERTOWN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of...
May 08, 2023 07:08 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience Launches ALSPAware to Provide Access to No-cost Genetic Testing and Counseling for Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP)

– New genetic testing initiative designed to enable improved patient diagnosis of ALSP, a devastating, rare genetic neurodegenerative disease – – Through ALSPAware, individuals and healthcare...
March 30, 2023 07:00 ET | Source: Vigil Neuroscience, Inc.

Vigil Neuroscience Announces FDA Has Lifted the Partial Clinical Hold on VGL101

WATERTOWN, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment...